Aclarion (ACON) Stock Price, News & Analysis

Company Overview

Aclarion, Inc. (NASDAQ: ACON) is a healthcare technology company focused on improving the diagnosis and treatment of chronic low back pain. The company develops tools intended to help physicians identify the spinal discs that may be contributing to a patient’s pain and support more informed treatment decisions.

Its principal product, Nociscan, is a cloud-based platform that analyzes data from magnetic resonance spectroscopy (MRS) and magnetic resonance imaging (MRI). By combining imaging information with proprietary algorithms and biochemical biomarkers, the platform is designed to provide physicians with additional objective information about disc health and potential pain generators.

Aclarion was formerly known as Nocimed and adopted the Aclarion name as it expanded its focus on data-driven spine care. The company markets its technology to healthcare providers and spine specialists in the United States and internationally. Its solutions are intended to complement, rather than replace, clinical evaluation and existing diagnostic imaging.

Key Stats

• Today's Range: $2.58 to $2.72
• 50-Day Range: $2.02 to $2.94
• 52-Week Range: $1.95 to $12.03
• Volume: 29,885 shs
• Average Volume: 47,916 shs
• Market Capitalization: $7.46 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $7.50
• Consensus Rating: Hold

Aclarion Stock Analysis - MarketRank™

Aclarion scored higher than 58% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.2 / 5
• Analyst Rating: Hold

Consensus Rating

Aclarion has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no strong buy ratings, 1 buy rating, no hold ratings, and 1 sell rating.

Upside Potential

Aclarion has a consensus price target of $7.50, representing about 189.6% upside from its current price of $2.59.

Amount of Analyst Coverage

Aclarion has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Aclarion are expected to decrease in the coming year, from ($4.51) to ($5.37) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Aclarion is -0.35, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Aclarion is -0.35, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Aclarion has a P/B Ratio of 0.17. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

2.64% of the float of Aclarion has been sold short.

Short Interest Ratio / Days to Cover

Aclarion has a short interest ratio ("days to cover") of 1.94, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Aclarion has recently increased by 206.89%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Aclarion does not currently pay a dividend.

Dividend Growth

Aclarion does not have a long track record of dividend growth.

News and Social Media

• Score: 1.5 / 5
• News Sentiment: 0.39

News Sentiment

Aclarion has a news sentiment score of 0.39. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.72 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 2 news articles for Aclarion this week, compared to 3 articles on an average week.

Company Ownership

• Score: 3.7 / 5
• Insider Trading: Acquiring Shares

Cluster Insider Buying

6 insiders have purchased shares of Aclarion in the last three months. Multiple insiders buying is a strong bullish signal.

Net Insider Buying

Over the last three months, insiders have purchased a net $125,670.00 in company stock, which represents 1.6848% of the company's market cap.

Insider Buying vs. Insider Selling

In the past three months, Aclarion insiders have bought more of their company's stock than they have sold. Specifically, they have bought $125,670.00 in company stock and sold $0.00 in company stock.

Percentage Held by Insiders

0.01% of the stock of Aclarion is held by insiders.

Percentage Held by Institutions

7.52% of the stock of Aclarion is held by institutions.

Company Calendar

• Last Earnings: 8/06/2026
• Today: 9/26/2026
• Lytham Partners Fall 2026 Investor Conference: 9/29/2026
• Next Earnings (Estimated): 11/11/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Healthcare Technology
• Sub-Industry: Healthcare Technology
• Current Symbol: NASDAQ:ACON
• CIK: 1635077
• Web: www.aclarion.com
• Phone: 833-275-2266
• Fax: N/A
• Employees: 11
• Year Founded: 2008

Price Target and Rating

• Average Price Target for Aclarion: $7.50
• High Price Target: $7.50
• Low Price Target: $7.50
• Potential Upside/Downside: +189.6%
• Consensus Rating: Hold
• Rating Score (0-4): 2.00
• Research Coverage: 2 Analysts

Profitability

• EPS (Trailing Twelve Months): ($7.40)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$7.23 million
• Net Margins: -10,948.81%
• Pretax Margin: -10,950.00%
• Return on Equity: -59.34%
• Return on Assets: -56.12%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 16.19
• Quick Ratio: 16.19

Sales & Book Value

• Annual Sales: $80 thousand
• Price / Sales: 93.24
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $15.02 per share
• Price / Book: 0.17

Miscellaneous

• Outstanding Shares: 2,880,000
• Free Float: 2,882,000
• Market Cap: $7.46 million
• Optionable: Not Optionable
• Beta: 1.24